Last edition
News about "ABL Bio Secures USD 40 Million"
ABL Bio Secures USD 40 Million Upfront, USD 15 Million Equity Investment From Eli Lilly
ABL Bio, a company focused on bispecific antibody technologies, announced that it will receive a USD 40 million upfront payment under a license, research, and collaboration agreement for its proprietary Grabody platform, along with a USD 15 million equity investment from Eli Lilly and Company.
ABL Bio Secures USD 40 Million | 29/12/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members